Outcomes in patients treated with frontline immune checkpoint inhibition (ICI) for advanced NSCLC with KRAS mutations and STK11/KEAP1 comutations across PD-L1 levels

KRAS mutations(m) are the most common oncogenic alterations in NSCLC, occurring in 20 –40 % of lung adenocarcinomas [1–3]. While KRAS has been historically considered undruggable, two KRAS G12C inhibitors are now FDA approved [4,5] and there is a suite of emerging KRAS-directed agents in development [6]. Understanding the relative therapeutic benefit of these novel agents, as w ell as designing clinical trials with prognostic balance between arms, will require a thorough understanding of outcomes and treatment responsiveness of KRASm aNSCLC across subgroups defined by KRASm subtype, PD-L1 status, and comutations.

Source: Lung Cancer - February 23, 2024 Category: Cancer & Oncology Authors: Lova Sun, Elizabeth A. Handorf, Yunyun Zhou, Hossein Borghaei, Charu Aggarwal, Jessica Bauman Source Type: research